Uroprotective effect of pantoprazole against cyclophosphamide-induced cystitis in mice

  • Seckin Engin
  • Elif Nur Barut
  • Burak Barut
  • Mine Kadioglu DumanEmail author
  • Cansu Kaya
  • Gokcen Kerimoglu
  • Arzu Ozel
Original Article



The aim of the present study was to evaluate the potential uroprotective effect of pantoprazole (PPZ) in a mouse model of cyclophosphamide (CP)-induced hemorrhagic cystitis (HC) due to its antioxidant and anti-inflammatory properties.


Balb/c mice received a single intraperitoneal (i.p.) injection of CP (300 mg/kg) to induce HC. PPZ (20, 50, and 100 mg/kg/day;i.p.) was administered for 3 consecutive days before the induction of HC. Mesna (30 mg/kg;i.p.) was administered 20 min before, 4 and 8 h after CP injection to compare the protective effects of PPZ. After 24 h of HC induction, the bladders were removed for functional studies, biochemical analyses, and histopathological examination.


In vitro contractility studies demonstrated that CP-induced HC decreased the responsiveness of detrusor muscle strips to acetylcholine (ACh), which was reversed by PPZ pretreatment at all doses tested. However, mesna treatment was not able to improve responsiveness to ACh. Biochemical analyses showed that CP caused significant elevation of malondialdehyde (MDA), reduction of total glutathione (GSH), and increment of proinflammatory cytokine tumor necrosis factor-alpha (TNF-α) level, which were measured in bladder homogenates. PPZ pretreatment at three doses found to be effective in reducing the CP-induced elevation of MDA and TNF-α levels. The highest dose of PPZ (100 mg/kg) caused a significant increase in GSH level. CP induced severe HC with marked bladder edema and histological disturbances which were partially abolished by PPZ pretreatment.


Our results indicate that PPZ pretreatment could attenuate CP-induced HC by interfering with oxidative stress and modulating proinflammatory cytokines.


Antioxidant Cyclophosphamide Detrusor contractility Hemorrhagic cystitis Pantoprazole Proinflammatory cytokine 


Funding information

This study was supported by a grant from the Scientific Research Project Coordination Unit of Karadeniz Technical University (Project no. THD-2018-7356).

Compliance with ethical standards

The experimental protocol was approved by the Local Ethics Committee of Faculty of Medicine (protocol approval number: 2016/29) as Institutional Review Board. All animal studies were performed according to the Guide for the Care and Use of Laboratory Animals.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Baumann F, Preiss R (2001) Cyclophosphamide and related anticancer drugs. J Chromatogr B 764(1–2):173–192CrossRefGoogle Scholar
  2. 2.
    Fleming RA (1997) An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 17(5):146–154Google Scholar
  3. 3.
    Mirkes PE (1985) Cyclophosphamide teratogenesis - a review. Teratogen Carcin Mut 5(2):75–88CrossRefGoogle Scholar
  4. 4.
    Patel JM (1987) Stimulation of cyclophosphamide-induced pulmonary microsomal lipid-peroxidation by oxygen. Toxicology 45(1):79–91CrossRefGoogle Scholar
  5. 5.
    Levine LA, Richie JP (1989) Urological complications of cyclophosphamide. J Urol 141(5):1063–1069CrossRefGoogle Scholar
  6. 6.
    Manikandan R, Kumar S, Dorairajan LN (2010) Hemorrhagic cystitis: a challenge to the urologist. Indian J Urol 26(2):159–166CrossRefGoogle Scholar
  7. 7.
    Korkmaz A, Topal T, Oter S (2007) Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol Toxicol 23(5):303–312CrossRefGoogle Scholar
  8. 8.
    Assreuy AMS, Martins GJ, Moreira MEF, Brito GAC, Cavada BS, Ribeiro RA et al (1999) Prevention of cyclophosphamide-induced hemorrhagic cystitis by glucose-mannose binding plant lectins. J Urol 161(6):1988–1993CrossRefGoogle Scholar
  9. 9.
    D'Cruz D, Haga HJ, Hughes GR (1991) Allergic reactions to mesna. Lancet 338(8768):705–706CrossRefGoogle Scholar
  10. 10.
    Sadir S, Deveci S, Korkmaz A, Oter S (2007) Alpha-tocopherol, beta-carotene and melatonin administration protects cyclophosphamide-induced oxidative damage to bladder tissue in rats. Cell Biochem Funct 25(5):521–526CrossRefGoogle Scholar
  11. 11.
    Hamsa TP, Kuttan G (2011) Protective role of Ipomoea obscura (L.) on cyclophosphamide-induced uro- and nephrotoxicities by modulating antioxidant status and pro-inflammatory cytokine levels. Inflammopharmacology 19(3):155–167CrossRefGoogle Scholar
  12. 12.
    Shin JM, Sachs G (2008) Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 10(6):528–534CrossRefGoogle Scholar
  13. 13.
    Boparai V, Rajagopalan J, Triadafilopoulos G (2008) Guide to the use of proton pump inhibitors in adult patients. Drugs 68(7):925–947CrossRefGoogle Scholar
  14. 14.
    Kedika RR, Souza RF, Spechler SJ (2009) Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci 54(11):2312–2317CrossRefGoogle Scholar
  15. 15.
    de Oliveira MG, Calmasini FB, Alexandre EC, De Nucci G, Monica FZ, Antunes E (2016) Activation of soluble guanylyl cyclase by BAY 58-2667 improves bladder function in cyclophosphamide-induced cystitis in mice. Am J Physiol Renal Physiol 311(1):F85–F93CrossRefGoogle Scholar
  16. 16.
    Keles I, Bozkurt MF, Cemek M, Karalar M, Hazini A, Alpdagtas S, Keles H, Yildiz T, Ceylan C, Buyukokuroglu ME (2014) Prevention of cyclophosphamide-induced hemorrhagic cystitis by resveratrol: a comparative experimental study with mesna. Int Urol Nephrol 46(12):2301–2310CrossRefGoogle Scholar
  17. 17.
    Histing T, Stenger D, Scheuer C, Metzger W, Garcia P, Holstein JH, Klein M, Pohlemann T, Menger MD (2012) Pantoprazole, a proton pump inhibitor, delays fracture healing in mice. Calcif Tissue Int 90(6):507–514CrossRefGoogle Scholar
  18. 18.
    Stocks J, Dormandy TL (1971) The autoxidation of human red cell lipids induced by hydrogen peroxide. Br J Haematol 20(1):95–111CrossRefGoogle Scholar
  19. 19.
    Donmez MI, Inci K, Zeybek ND, Dogan HS, Ergen A (2016) The early histological effects of Intravesical instillation of platelet-rich plasma in cystitis models. Int Neurourol J 20(3):188–196CrossRefGoogle Scholar
  20. 20.
    Gomes TN, Santos CC, Souza-Filho MV, Cunha FQ, Ribeiro RA (1995) Participation of TNF-alpha and IL-1 in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis. Braz J Med Biol Res 28(10):1103–1108Google Scholar
  21. 21.
    Ribeiro RA, Freitas HC, Campos MC, Santos CC, Figueiredo FC, Brito GA et al (2002) Tumor necrosis factor-alpha and interleukin-1beta mediate the production of nitric oxide involved in the pathogenesis of ifosfamide induced hemorrhagic cystitis in mice. J Urol 167(5):2229–2234CrossRefGoogle Scholar
  22. 22.
    Korkmaz A, Oter S, Deveci S, Ozgurtas T, Topal T, Sadir S et al (2003) Involvement of nitric oxide and hyperbaric oxygen in the pathogenesis of cyclophosphamide induced hemorrhagic cystitis in rats. J Urol 170(6 Pt 1):2498–2502CrossRefGoogle Scholar
  23. 23.
    Droller MJ, Saral R, Santos G (1982) Prevention of cyclophosphamide-induced hemorrhagic cystitis. Urology 20(3):256–258CrossRefGoogle Scholar
  24. 24.
    Andersson KE, Arner A (2004) Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 84(3):935–986CrossRefGoogle Scholar
  25. 25.
    Giglio D, Ryberg AT, To K, Delbro DS, Tobin G (2005) Altered muscarinic receptor subtype expression and functional responses in cyclophosphamide induced cystitis in rats. Auton Neurosci-Basic 122(1–2):9–20CrossRefGoogle Scholar
  26. 26.
    Kageyama A, Fujino T, Taki Y, Kato Y, Nozawa Y, Ito Y, Yamada S (2008) Alteration of muscarinic and purinergic receptors in urinary bladder of rats with cyclophosphamide-induced interstitial cystitis. Neurosci Lett 436(1):81–84CrossRefGoogle Scholar
  27. 27.
    Sugino Y, O'Malley KJ, Wang Z, Tyagi P, Birder LA, Ogawa O et al (2015) Laser-capture microdissection for analysis of cell type-specific gene expression of muscarinic receptor subtypes in the rat bladder with cyclophosphamide-induced cystitis. Int Urol Nephrol 47(4):637–642CrossRefGoogle Scholar
  28. 28.
    Giglio D, Aronsson P, Eriksson L, Tobin G (2007) In vitro characterization of parasympathetic and sympathetic responses in cyclophosphamide-induced cystitis in the rat. Basic Clin Pharmacol Toxicol 100(2):96–108CrossRefGoogle Scholar
  29. 29.
    Liu M, Shen S, Kendig DM, Mahavadi S, Murthy KS, Grider JR, Qiao LY (2015) Inhibition of NMDAR reduces bladder hypertrophy and improves bladder function in cyclophosphamide induced cystitis. J Urol 193(5):1676–1683CrossRefGoogle Scholar
  30. 30.
    Ayala A, Munoz MF, Arguelles S (2014) Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-Hydroxy-2-Nonenal. Oxidative Med Cell Longev 2014:1–31CrossRefGoogle Scholar
  31. 31.
    Sinanoglu O, Yener AN, Ekici S, Midi A, Aksungar FB (2012) The protective effects of spirulina in cyclophosphamide induced nephrotoxicity and urotoxicity in rats. Urology 80(6):1392.e1–1392.e6CrossRefGoogle Scholar
  32. 32.
    Fornai M, Colucci R, Antonioli L, Ghisu N, Tuccori M, Blandizzi C, del Tacca M (2009) Effects of pantoprazole on ulcer healing delay associated with NSAID treatment. Naunyn Schmiedeberg's Arch Pharmacol 379(3):305–313CrossRefGoogle Scholar
  33. 33.
    Blandizzi C, Fornai M, Colucci R, Natale G, Lubrano V, Vassalle C, Antonioli L, Lazzeri G, del Tacca M (2005) Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. World J Gastroenterol 11(26):4052–4060CrossRefGoogle Scholar
  34. 34.
    Biswas K, Bandyopadhyay U, Chattopadhyay I, Varadaraj A, Ali E, Banerjee RK (2003) A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J Biol Chem 278(13):10993–11001CrossRefGoogle Scholar
  35. 35.
    Simon WA, Sturm E, Hartmann HJ, Weser U (2006) Hydroxyl radical scavenging reactivity of proton pump inhibitors. Biochem Pharmacol 71(9):1337–1341CrossRefGoogle Scholar
  36. 36.
    Bhatia K, Ahmad F, Rashid H, Raisuddin S (2008) Protective effect of S-allylcysteine against cyclophosphamide-induced bladder hemorrhagic cystitis in mice. Food Chem Toxicol 46(11):3368–3374CrossRefGoogle Scholar
  37. 37.
    Fornai M, Natale G, Colucci R, Tuccori M, Carazzina G, Antonioli L, Baldi S, Lubrano V, Abramo A, Blandizzi C, del Tacca M (2005) Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage. Naunyn Schmiedebergs Arch Pharmacol 372(1):79–87CrossRefGoogle Scholar
  38. 38.
    Pastoris O, Verri M, Boschi F, Kastsiuchenka O, Balestra B, Pace F, Tonini M, Natale G (2008) Effects of esomeprazole on glutathione levels and mitochondrial oxidative phosphorylation in the gastric mucosa of rats treated with indomethacin. Naunyn Schmiedeberg's Arch Pharmacol 378(4):421–429CrossRefGoogle Scholar
  39. 39.
    Hamsa TP, Kuttan G (2012) Tinospora cordifolia ameliorates urotoxic effect of cyclophosphamide by modulating GSH and cytokine levels. Exp Toxicol Pathol 64(4):307–314CrossRefGoogle Scholar
  40. 40.
    Gore PR, Prajapati CP, Mahajan UB, Goyal SN, Belemkar S, Ojha S, Patil CR (2016) Protective effect of thymoquinone against cyclophosphamide-induced hemorrhagic cystitis through inhibiting DNA damage and upregulation of Nrf2 expression. Int J Biol Sci 12(8):944–953CrossRefGoogle Scholar
  41. 41.
    Rodriguez-Antona C, Ingelman-Sundberg M (2006) Cytochrome P450 pharmacogenetics and cancer. Oncogene. 25(11):1679–1691CrossRefGoogle Scholar
  42. 42.
    Wedemeyer RS, Blume H (2014) Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf 37(4):201–211CrossRefGoogle Scholar
  43. 43.
    Savarino V, Di Mario F, Scarpignato C (2009) Proton pump inhibitors in GORD an overview of their pharmacology, efficacy and safety. Pharmacol Res 59(3):135–153CrossRefGoogle Scholar
  44. 44.
    Spugnini E, Fais S (2017) Proton pump inhibition and cancer therapeutics: a specific tumor targeting or it is a phenomenon secondary to a systemic buffering? Semin Cancer Biol 43:111–118CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pharmacology, Faculty of PharmacyKaradeniz Technical UniversityTrabzonTurkey
  2. 2.Department of Biochemistry, Faculty of PharmacyKaradeniz Technical UniversityTrabzonTurkey
  3. 3.Department of Pharmacology, Faculty of MedicineKaradeniz Technical UniversityTrabzonTurkey
  4. 4.Department of Histology and Embryology, Faculty of MedicineKaradeniz Technical UniversityTrabzonTurkey

Personalised recommendations